EPHX2 and type 2 diabetes mellitus: Two clinical trials are still undergoing evaluation—the first one, referred as to NCT03486223, tests whether a given genetic variant in EPHX2 (p.Arg287Gln) is associated with insulin sensitivity, and evaluates the effects of EPHX2 inhibition on type 2 diabetes; the second, referred as to NCT03318783, aims to evaluate the efficacy of EPHX2 inhibition in patients with aneurysmal subarachnoid hemorrhage [91].